This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Glenmark Pharmaceuticals S.a.. Active years: 2014.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2014
Title: Christophe Debonneville: Innovator in Humanized Antibodies
Introduction
Christophe Debonneville is a notable inventor based in La Chaux-de-Fonds, Switzerland. He has made significant contributions to the field of biotechnology, particularly in the development of humanized antibodies.
Latest Patents
Debonneville holds a patent for "Humanized antibodies that bind to CD19 and their uses." This invention relates to humanized antibodies or fragments that specifically bind to human CD19. The patent details a humanized antibody or fragment that includes specific amino acid sequences for heavy and light chain CDRs, which are crucial for binding to CD19.
Career Highlights
Christophe Debonneville is associated with Glenmark Pharmaceuticals S.A., where he applies his expertise in antibody development. His work focuses on advancing therapeutic options for diseases that involve CD19, which is a significant target in cancer treatment.
Collaborations
Debonneville collaborates with notable colleagues, including Stanislas Blein and Darko Skegro, who contribute to the innovative environment at Glenmark Pharmaceuticals.
Conclusion
Christophe Debonneville's work in humanized antibodies represents a vital advancement in biotechnology, showcasing his commitment to improving therapeutic strategies. His contributions continue to influence the field and offer hope for future medical breakthroughs.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile